US Patent Issued to Seyltx on Nov. 18 for "Use of glutamate 2B receptor antagonists and sigma receptor agonists as antitussives" (Canadian Inventor)

ALEXANDRIA, Va., Nov. 18 -- United States Patent no. 12,472,170, issued on Nov. 18, was assigned to Seyltx Inc. (Pittsburgh).

"Use of glutamate 2B receptor antagonists and sigma receptor agonists as antitussives" was invented by Mark Williams (Winnipeg, Canada).

According to the abstract* released by the U.S. Patent & Trademark Office: "The use of glutamate 2b receptor antagonists and sigma receptor agonists as antitussives to treat or prevent a cough is disclosed. In preferred embodiments, the glutamate 2b receptor antagonist is ifenprodil or radiprodil. Preferred sigma receptor agonists include fluvoxamine, fluoxetine, excitalpram, and donepezil."

The patent was filed on March 6, 2020, under Application No. 17/771,664.

*For further in...